MX2025001237A - Celulas modificadas geneticamente con expresion genica reducida para mitigar el reconocimiento de celulas inmunitarias - Google Patents

Celulas modificadas geneticamente con expresion genica reducida para mitigar el reconocimiento de celulas inmunitarias

Info

Publication number
MX2025001237A
MX2025001237A MX2025001237A MX2025001237A MX2025001237A MX 2025001237 A MX2025001237 A MX 2025001237A MX 2025001237 A MX2025001237 A MX 2025001237A MX 2025001237 A MX2025001237 A MX 2025001237A MX 2025001237 A MX2025001237 A MX 2025001237A
Authority
MX
Mexico
Prior art keywords
cells
engineered
express
gene expression
immune cell
Prior art date
Application number
MX2025001237A
Other languages
English (en)
Inventor
Cesar Adolfo Sommer
Hsin - Yuan CHENG
Barbra Johnson Sasu
Original Assignee
Allogene Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allogene Therapeutics Inc filed Critical Allogene Therapeutics Inc
Publication of MX2025001237A publication Critical patent/MX2025001237A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/15—Natural-killer [NK] cells; Natural-killer T [NKT] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/421—Immunoglobulin superfamily
    • A61K40/4211—CD19 or B4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0646—Natural killers cells [NK], NKT cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/50—Cellular immunotherapy characterised by the use of allogeneic cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)

Abstract

En la presente descripción se proporcionan células inmunitarias modificadas genéticamente y poblaciones de estas para su administración a sujetos para tratar el cáncer (por ejemplo, tumores sólidos o tumores líquidos) y otras afecciones. Las células se modifican genéticamente para expresar funcionalmente un nivel reducido de uno o más de CD48, CD58, ICAM-1, RFX5, NLRC5, TAP2, ß2m, TRAC, RFXAP, CIITA y RFXANK. Las células opcionalmente se modifican genéticamente de manera adicional para expresar una o más de una proteína adicional tal como una proteína de unión a antígenos (por ejemplo, un receptor de antígeno quimérico (CAR) o receptor de células T) y/o una proteína de unión a CD70 para dirigirse a células tumorales u otras células dañadas en el sujeto y/o para expresar otros genes a un nivel reducido. También se proporcionan métodos para fabricar y usar las células modificadas genéticamente, composiciones y kits que las comprenden, y métodos para tratar mediante la administración de las células y las composiciones.
MX2025001237A 2022-07-29 2025-01-29 Celulas modificadas geneticamente con expresion genica reducida para mitigar el reconocimiento de celulas inmunitarias MX2025001237A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263393350P 2022-07-29 2022-07-29
US202363509136P 2023-06-20 2023-06-20
PCT/US2023/071188 WO2024026445A1 (en) 2022-07-29 2023-07-28 Engineered cells with reduced gene expression to mitigate immune cell recognition

Publications (1)

Publication Number Publication Date
MX2025001237A true MX2025001237A (es) 2025-03-07

Family

ID=87748241

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2025001237A MX2025001237A (es) 2022-07-29 2025-01-29 Celulas modificadas geneticamente con expresion genica reducida para mitigar el reconocimiento de celulas inmunitarias

Country Status (8)

Country Link
US (1) US20240042030A1 (es)
EP (1) EP4562134A1 (es)
JP (1) JP2025525779A (es)
CN (1) CN119654406A (es)
AU (1) AU2023312973A1 (es)
CA (1) CA3261440A1 (es)
MX (1) MX2025001237A (es)
WO (1) WO2024026445A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202444898A (zh) * 2023-04-21 2024-11-16 美商凱特製藥公司 免疫排斥之風險降低的同種異體治療性細胞
WO2025231191A1 (en) * 2024-05-01 2025-11-06 Cargo Therapeutics, Inc. Compositions and methods for allogeneic immune cells

Family Cites Families (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4754065A (en) 1984-12-18 1988-06-28 Cetus Corporation Precursor to nucleic acid probe
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US4800159A (en) 1986-02-07 1989-01-24 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences
GB8611832D0 (en) 1986-05-15 1986-06-25 Holland I B Polypeptide
US5037743A (en) 1988-08-05 1991-08-06 Zymogenetics, Inc. BAR1 secretion signal
US5858358A (en) 1992-04-07 1999-01-12 The United States Of America As Represented By The Secretary Of The Navy Methods for selectively stimulating proliferation of T cells
US6905680B2 (en) 1988-11-23 2005-06-14 Genetics Institute, Inc. Methods of treating HIV infected subjects
US6534055B1 (en) 1988-11-23 2003-03-18 Genetics Institute, Inc. Methods for selectively stimulating proliferation of T cells
US6352694B1 (en) 1994-06-03 2002-03-05 Genetics Institute, Inc. Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells
US7175843B2 (en) 1994-06-03 2007-02-13 Genetics Institute, Llc Methods for selectively stimulating proliferation of T cells
US6692964B1 (en) 1995-05-04 2004-02-17 The United States Of America As Represented By The Secretary Of The Navy Methods for transfecting T cells
US7067318B2 (en) 1995-06-07 2006-06-27 The Regents Of The University Of Michigan Methods for transfecting T cells
US6011138A (en) 1997-02-20 2000-01-04 Idec Pharmaceuticals Corporation Gamma-1 anti-human CD23 monoclonal antibodies
US7572631B2 (en) 2000-02-24 2009-08-11 Invitrogen Corporation Activation and expansion of T cells
US6797514B2 (en) 2000-02-24 2004-09-28 Xcyte Therapies, Inc. Simultaneous stimulation and concentration of cells
US6867041B2 (en) 2000-02-24 2005-03-15 Xcyte Therapies, Inc. Simultaneous stimulation and concentration of cells
DK1257632T3 (da) 2000-02-24 2008-01-28 Xcyte Therapies Inc Samtidig stimulering og opkoncentrering af celler
EP1334188B1 (en) 2000-11-07 2006-08-30 City of Hope Cd19-specific redirected immune cells
JP4463475B2 (ja) 2001-01-31 2010-05-19 バイオジェン アイデック インコーポレイテッド 腫瘍疾患の治療における免疫調節性抗体の使用
WO2004006955A1 (en) 2001-07-12 2004-01-22 Jefferson Foote Super humanized antibodies
EP2186896B1 (en) 2004-03-31 2015-11-04 International Institute of Cancer Immunology, Inc. Cancer antigen peptides derived from WT1
ES2621874T3 (es) 2010-03-26 2017-07-05 Memorial Sloan-Kettering Cancer Center Anticuerpos para MUC16 y métodos de uso de los mismos
WO2014016817A2 (en) 2012-07-17 2014-01-30 Universite De Geneve Nucleic acids for down-regulation of gene expression
US11077144B2 (en) 2013-05-13 2021-08-03 Cellectis CD19 specific chimeric antigen receptor and uses thereof
EP3039040B1 (en) 2013-08-26 2021-12-22 Hinrich Abken Anti cd30 chimeric antigen receptor and its use
US20160152725A1 (en) 2014-02-25 2016-06-02 Memorial Sloan-Kettering Cancer Center Antigen-binding proteins specific for hla-a2-restricted wilms tumor 1 peptide
BR112017001242A2 (pt) 2014-07-21 2017-12-05 Novartis Ag tratamento de câncer usando um receptor antigênico quimérico a cd33
WO2016014565A2 (en) 2014-07-21 2016-01-28 Novartis Ag Treatment of cancer using humanized anti-bcma chimeric antigen receptor
GB201413335D0 (en) 2014-07-28 2014-09-10 Azotic Technologies Ltd Agricultural methods
RU2017102769A (ru) 2014-07-29 2018-08-28 Пфайзер Инк. EGFRvIII СПЕЦИФИЧЕСКИЕ ХИМЕРНЫЕ АНТИГЕННЫЕ РЕЦЕПТОРЫ ДЛЯ ИММУНОТЕРАПИИ РАКА
NZ733841A (en) 2015-01-16 2024-01-26 Juno Therapeutics Inc Antibodies and chimeric antigen receptors specific for ror1
CA2973529A1 (en) 2015-01-26 2016-08-04 Cellectis Cll1-specific multi-chain chimeric antigen receptor
MX391249B (es) 2015-03-17 2025-03-21 Memorial Sloan Kettering Cancer Center Anticuerpos anti-muc16 y sus usos.
CN107921127B (zh) 2015-05-22 2022-04-08 纪念斯隆-凯特琳癌症中心 对于prame肽具有特异性的t细胞受体样抗体
CN105384825B (zh) 2015-08-11 2018-06-01 南京传奇生物科技有限公司 一种基于单域抗体的双特异性嵌合抗原受体及其应用
WO2017025323A1 (en) 2015-08-11 2017-02-16 Cellectis Cells for immunotherapy engineered for targeting cd38 antigen and for cd38 gene inactivation
US10815301B2 (en) 2015-10-15 2020-10-27 The United States Of America, As Represented By The Secretary, Department Of Health And Human Service Anti-CD30 chimeric antigen receptors
US10259876B2 (en) 2016-01-21 2019-04-16 Pfizer Inc. Chimeric antigen receptors targeting epidermal growth factor receptor variant III
PE20190201A1 (es) 2016-04-01 2019-02-05 Amgen Inc Receptores quimericos de flt3 y metodos de uso de los mismos
US11414497B2 (en) 2016-04-13 2022-08-16 Orimabs Ltd. Anti-PSMA antibodies and use thereof
WO2018006882A1 (zh) 2016-07-08 2018-01-11 科济生物医药（上海）有限公司 抗密蛋白18a2的抗体及其应用
EP3529279A4 (en) 2016-10-19 2020-04-29 The Governing Council of the University of Toronto CD133 BINDERS AND USE THEREOF
CN108395482B (zh) 2017-02-08 2021-02-05 西比曼生物科技（香港）有限公司 一种靶向cd20抗原嵌合抗原受体的构建及其工程化t细胞的活性鉴定
TWI785009B (zh) 2017-02-14 2022-12-01 美商凱特製藥公司 Ｃｄ７０結合分子及使用彼之方法
MY201327A (en) 2017-06-02 2024-02-16 Pfizer Chimeric antigen receptors targeting flt3
WO2019030240A1 (en) 2017-08-07 2019-02-14 Nbe-Therapeutics Ag ANTIBODIES BINDING TO A LINEAR HUMAN CS1 EPITOPE
CN112020518A (zh) 2018-02-01 2020-12-01 辉瑞公司 靶向cd70的嵌合抗原受体
CN116836297A (zh) 2018-04-12 2023-10-03 上海赛比曼生物科技有限公司 靶向bcma的嵌合抗原受体及其制法和应用
US20210269501A1 (en) 2018-06-25 2021-09-02 The Trustees Of The University Of Pennsylvania Compositions and methods of nkg2d chimeric antigen receptor t cells for controlling triple-negative breast cancer
US20210301024A1 (en) 2018-07-04 2021-09-30 Cytoimmune Therapeutics, Inc. Compositions and methods for immunotherapy targeting flt3, pd-1, and/or pd-l1
WO2020010235A1 (en) 2018-07-05 2020-01-09 H. Lee Moffitt Cancer Center And Research Institute Inc. Car t cells that target b-cell antigens
CN113039197A (zh) 2018-07-26 2021-06-25 T细胞受体治疗公司 使用靶特异性融合蛋白进行tcr重编程的组合物和方法
BR112021008082A2 (pt) 2018-11-07 2021-08-10 Crispr Therapeutics Ag terapia contra o câncer com células imunitárias anti-liv1
CN109468284A (zh) 2018-11-30 2019-03-15 北京美康基免生物科技有限公司 一种基于cd19和psma的双重嵌合抗原受体基因修饰的免疫细胞及其应用
IL283734B2 (en) 2018-12-12 2025-03-01 Kite Pharma Inc Chimeric antigen receptors and CAR-T cells and methods of use
CN109680002A (zh) 2019-01-09 2019-04-26 上海怡豪生物科技有限公司 联合msln单链抗体和ccl19杀伤胃癌细胞的car载体及其构建方法和应用
CN109628492A (zh) 2019-01-09 2019-04-16 上海怡豪生物科技有限公司 联合MSLN单链抗体和PD-1mAb杀伤胃癌细胞的CAR载体及其构建方法和应用
PT3749338T (pt) 2019-01-16 2024-09-20 Caribou Biosciences Inc Anticorpo de bcma humanizado e células bcma-car-t
US11738050B2 (en) 2019-02-01 2023-08-29 Regents Of The University Of Minnesota Compounds binding to fibroblast activation protein alpha
KR20210138574A (ko) 2019-03-01 2021-11-19 알로젠 테라퓨틱스 인코포레이티드 Dll3 표적화 키메라 항원 수용체 및 결합제
WO2020186204A1 (en) 2019-03-13 2020-09-17 Ulmert Hans David Staffan Prame binding molecules and uses thereof
EP3969035A4 (en) 2019-05-14 2023-06-21 Werewolf Therapeutics, Inc. SEPARATION UNITS AND METHODS AND THEIR USE
CN116041512A (zh) 2019-07-12 2023-05-02 明济生物制药（北京）有限公司 Cldn18.2抗体及其用途
AU2021227191A1 (en) 2020-02-24 2022-08-25 Allogene Therapeutics, Inc. BCMA car-T cells with enhanced activities
CN111363046A (zh) 2020-03-11 2020-07-03 深圳宾德生物技术有限公司 靶向nkg2d的嵌合抗原受体、嵌合抗原受体t细胞及其制备方法和应用
KR20230142470A (ko) * 2021-01-29 2023-10-11 알로젠 테라퓨틱스 인코포레이티드 동종이계 세포 산물의 T 세포 인식을 완화하기 위한TAP2, NLRC5, β2m, TRAC, RFX5, RFXAP, 및 RFXANK 중 하나 이상의 녹다운 또는 녹아웃

Also Published As

Publication number Publication date
JP2025525779A (ja) 2025-08-07
AU2023312973A1 (en) 2025-01-09
US20240042030A1 (en) 2024-02-08
CA3261440A1 (en) 2024-02-01
CN119654406A (zh) 2025-03-18
WO2024026445A1 (en) 2024-02-01
EP4562134A1 (en) 2025-06-04

Similar Documents

Publication Publication Date Title
Zhang et al. Challenges and new technologies in adoptive cell therapy
US12263220B2 (en) Compositions and methods for immunotherapy
MX2025001237A (es) Celulas modificadas geneticamente con expresion genica reducida para mitigar el reconocimiento de celulas inmunitarias
JP6857028B2 (ja) 免疫治療のための組成物および方法
JP7546925B2 (ja) 核酸とｃａｒ修飾免疫細胞とを含む治療薬およびその使用
Olivera et al. mRNAs encoding IL-12 and a decoy-resistant variant of IL-18 synergize to engineer T cells for efficacious intratumoral adoptive immunotherapy
JP2017525385A (ja) 細胞治療物質としてのｃａｒ発現ｎｋ−９２細胞
WO2020163365A3 (en) Combination gene targets for improved immunotherapy
Wu et al. HER2-specific chimeric antigen receptor-engineered natural killer cells combined with apatinib for the treatment of gastric cancer
WO2017084421A1 (zh) 一种包含高效杀伤启动机制的肿瘤精准t细胞及其用途
MX2023008809A (es) ATENUACIÓN O INACTIVACIÓN DE UNO O MÁS DE TAP2, NLRC5, ß2M, TRAC, RFX5, RFXAP Y RFXANK PARA MITIGAR EL RECONOCIMIENTO DE CÉLULAS T DE PRODUCTOS CELULARES ALOGÉNICOS.
JP2022509017A (ja) 抗ｐｔｋ７免疫細胞癌療法
JP2022513586A (ja) 抗ｌｉｖ１免疫細胞癌療法
WO2019080538A1 (zh) 嵌合抗原受体、其修饰的NK细胞、编码 DNA、mRNA、表达载体、制备方法和应用
AU2021234454B2 (en) Application of IFN-gamma in preparing anti-tumor adjuvant drug
EP4294822A1 (en) Enhancing metabolic fitness of t cells to treat cancer
CN113454115A (zh) 靶向唾液酸化路易斯a的嵌合抗原受体及其用途
Li et al. Precision sniper for solid tumors: CAR-NK cell therapy
KR101651171B1 (ko) Il-12를 발현하는 간엽 줄기세포를 포함하는 간암 치료용 조성물 및 이를 이용한 치료방법
US20230355762A1 (en) Compositions and methods for the treatment of cancer using next generation engineered t cell therapy
WO2022020860A3 (en) Engineered t cells and tumor-infiltrating lymphocytes to increase tumor killing
Ioachim et al. Antigenic deletion and malignant enhancement induced in lymphoma cells by passage through X-irradiated hosts
CN114096670B (zh) 激活免疫系统的细胞和包含该细胞的药物组合物
Nabizadeh et al. An Engineered Mesenchymal Stem Cell by Lentiviral Vector Expressing CD44 as a Candidate to Target Colon Cancer Tissue in Mice Model
Huang et al. CAR-NK cell for gynecological cancers: immune microenvironment remodeling and immunotherapeutic strategies